Trial Profile
2-part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part A - Open-label, Single-arm, Multicenter Pilot Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part B - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms PROFICIO; TESLA
- Sponsors Amgen
- 01 Oct 2014 According to an Amgen media release, results from phase III portion were published in The Lancet.
- 01 Oct 2014 Amgen plans to submit regulatory filings to US and EU for evolocumab based on the data from TESLA, RUTHERFORD-2 and few other studies in the clinical trial programme.
- 09 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.